TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04824092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT05190705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally or administered by intravenous infusion
Study: NCT05465109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TBI-AD/ADRD Caregiver Support Intervention (TACSI)
Description: The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
Study: NCT06025240

Intervention type: DIAGNOSTIC_TEST
Intervention: cf-DNA
Description: In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunological Events following renal transplant in older age
Description: Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).

Intervention type: OTHER
Intervention: Determining Predictive Models for Post-transplant HLA-specific Antibody Formation
Description: A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
Study: NCT04824092

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06584227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and Chidamide Combined with Gemcitabine and S1
Description: Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.
Study: NCT06584123

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro-ethyl-tyrosine (FET) PET
Description: 18F-Fluoro-ethyl-tyrosine PET study of the pituitary
Study: NCT06583681

Intervention type: OTHER
Group type: OTHER
Intervention: The measuring of the sagittal curvatures of the spine
Description: Research tool was Baseline Bubble inclinometer.
Study: NCT04824092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study: NCT05150938

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Intervention type: DRUG
Intervention: Low molecular weight heparin (LMWH)
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Intervention type: DRUG
Intervention: vitamin K antagonist (VKA)
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Intervention type: DRUG
Intervention: other NOACs
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study: NCT06296485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAGE Group Sessions
Description: Participants enroll in 3 educational group sessions and receive CGMs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants continue to receive usual care (Control Arm)
Study: NCT05547217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Therapy using the MyHand System
Description: The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
Study: NCT05691205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: After a recruitment maneuver three levels of PEEP (14\>10\>6cmH2O) will be tested
Study: NCT05492916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP)
Description: Video-based intervention to prevent or delay Type 2 Diabetes. Includes both educational and social cognitive theory (SCT)-based behavioral content. Each video lasts about 5 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Supported Agriculture (CSA)
Description: Provides weekly and culturally appropriate fresh produce and in-language education on nutrition, healthy cooking demonstrations, and culturally tailored recipes for participants. Enables participants to socialize with other Chinese immigrants in the program as a way to enhance social cohesion and support.
Study: NCT04968184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will orally receive placebo matching to KBP-5074 tablets QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
Study: NCT05873790

Intervention type: DRUG
Intervention: Serplulimab plus chemotherapy
Description: Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.
Study: NCT05318872

Intervention type: DEVICE
Intervention: ENDOSWIR
Description: Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
Study: NCT05218525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter.
Study: NCT05830071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5993
Description: BDP/FF/GB 100/6/12.5 μg pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5993
Description: BDP/FF/GB 100/6/12.5 μg pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259
Description: GB 12.5 μg pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: 400 mg Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF5993 Placebo
Description: placebo pMDI
Study: NCT04824092

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tafasitamab placebo
Description: 0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT05830071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5993 Placebo
Description: placebo pMDI
Study: NCT04824092

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide placebo
Description: Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study: NCT05972850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivo Heart
Description: Vivo is an online, live, small group fitness program developed for older adults that uses individually tailored dual-tasked (i.e., cognitive-motor) exercises to improve strength, endurance, balance, and cognition and incorporates social engagement. Certified trainers deliver instruction and coaching through an interactive session for 45 min, 2-3 times/week.
Study: NCT05762406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory protective mask
Description: Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)
Study: NCT05748457

Intervention type: BEHAVIORAL
Intervention: Non-manualised family therapy.
Description: Family therapy provided by qualified therapists without reference to a specific therapy manual.

Intervention type: BEHAVIORAL
Intervention: Family Based Treatment
Description: Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015).
Study: NCT05107765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill capsules will look same as that of active drug.
Study: NCT05393973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises along with conventional physical therapy
Description: Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss ball exercises along with the conventional physical therapy protocol
Description: Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
Study: NCT04868760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Study: NCT04936711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resteck Shiatsu Neck and Back Massager
Description: back massager device sold on the market that can readily be purchased online or in store

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: Marcaine spray at incision site after closure
Study: NCT04868760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Study: NCT05101668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Thrombosis Aspiration Catheter
Description: Direct Aspiration
Study: NCT06372691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subparaneural Injection (Grup S), Block
Description: Comparison of two different methods in terms of various features

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interneural Injection (Grup I), Block
Description: Comparison of two different methods in terms of various features
Study: NCT06650007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: HRS9531 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: HRS9531 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 Placebo Injection
Description: HRS9531 Placebo Injection
Study: NCT06253169

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV DNA self-test
Description: HPV DNA swab from the cervix performed by the patient herself.

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV DNA self-test
Description: HPV DNA swab from the cervix performed by the patient herself.
Study: NCT06650007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 Placebo Injection
Description: HRS9531 Placebo Injection
Study: NCT06409442

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program
Description: Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program
Description: Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Program
Description: Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: In addition to the standard physiotherapy program, kinesio taping (device) will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy
Description: In addition to the standard physiotherapy program, local vibration (device) will be applied.
Study: NCT05299840

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oncogramme results available
Description: in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oncogramme results unavailable
Description: in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
Study: NCT06359977

Intervention type: OTHER
Intervention: Quantitative EEG monitoring and beside ultrasound evaluation
Description: After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
Study: NCT05734586

Intervention type: OTHER
Group type: OTHER
Intervention: EAT-10 (Eating assessment Tool) screening questionnaire
Description: After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective measures for the upper airways
Description: In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures
Study: NCT05884606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allurion Digital Behaviour Change Intervention
Description: The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
Study: NCT04436965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized nutrition therapy
Description: Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study: NCT05779410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium-chain triglycerides
Description: Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
Study: NCT04796454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
Study: NCT05804344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal speech motor tDCS
Description: tDCS montage set for Anode: C5; Cathode: Fp2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal speech motor tDCS
Description: tDCS montage set for Anode: Fp2; Cathode: C5

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal IFG tDCS
Description: tDCS montage set for Anode: F3; Cathode: Fp2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal IFG tDCS
Description: tDCS montage set for Anode: Fp2; Cathode: F3

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS device set in Sham mode